Sangamo Therapeutics (SGMO) Upgraded to Strong-Buy by BidaskClub

BidaskClub upgraded shares of Sangamo Therapeutics (NASDAQ:SGMO) from a buy rating to a strong-buy rating in a research report sent to investors on Saturday.

Several other equities analysts also recently issued reports on SGMO. Piper Jaffray Companies raised shares of Sangamo Therapeutics from a neutral rating to an overweight rating and set a $19.00 price target for the company in a report on Wednesday, November 15th. Zacks Investment Research raised shares of Sangamo Therapeutics from a hold rating to a buy rating and set a $14.00 price target for the company in a report on Wednesday, November 15th. Wedbush reissued a hold rating and set a $6.00 price target on shares of Sangamo Therapeutics in a report on Wednesday, November 15th. Finally, Barclays started coverage on shares of Sangamo Therapeutics in a report on Wednesday, November 22nd. They set an overweight rating and a $20.00 price target for the company. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $18.83.

Sangamo Therapeutics (NASDAQ SGMO) opened at $23.30 on Friday. Sangamo Therapeutics has a 1-year low of $3.65 and a 1-year high of $23.75. The stock has a market cap of $1,970.00, a price-to-earnings ratio of -33.77 and a beta of 2.87. The company has a current ratio of 5.64, a quick ratio of 5.64 and a debt-to-equity ratio of 0.02.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The company had revenue of $11.81 million during the quarter, compared to the consensus estimate of $10.37 million. During the same quarter in the previous year, the company posted ($0.27) earnings per share. The company’s revenue for the quarter was up 333.0% compared to the same quarter last year. sell-side analysts expect that Sangamo Therapeutics will post -0.73 EPS for the current year.

In related news, Director Steven J. Mento sold 11,520 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $20.59, for a total value of $237,196.80. Following the completion of the sale, the director now owns 5,000 shares of the company’s stock, valued at $102,950. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Curt A. Herberts III sold 16,630 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $16.13, for a total transaction of $268,241.90. The disclosure for this sale can be found here. Insiders sold 84,953 shares of company stock valued at $1,544,843 in the last ninety days. Corporate insiders own 5.50% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Quantbot Technologies LP acquired a new stake in Sangamo Therapeutics in the third quarter worth about $118,000. Virtu KCG Holdings LLC acquired a new stake in Sangamo Therapeutics in the second quarter worth about $124,000. Fred Alger Management Inc. acquired a new stake in Sangamo Therapeutics in the fourth quarter worth about $148,000. Amalgamated Bank acquired a new stake in Sangamo Therapeutics in the third quarter worth about $158,000. Finally, Great West Life Assurance Co. Can lifted its holdings in Sangamo Therapeutics by 150.3% in the third quarter. Great West Life Assurance Co. Can now owns 12,767 shares of the biopharmaceutical company’s stock worth $182,000 after purchasing an additional 7,667 shares during the period. 68.93% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This report was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://stocknewstimes.com/2018/02/20/sangamo-therapeutics-sgmo-upgraded-to-strong-buy-by-bidaskclub.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply